Back to today’s briefing

Story perspectives

FDA Approves Sotagliflozin: Slashes Heart Attack Risk 23%

2/15/2025

49 4

Summary

Story summary

Sotagliflozin, now FDA-approved for type 2 diabetes and kidney disease, is a game-changer in heart health. A groundbreaking trial led by Mount Sinai revealed that this innovative treatment slashed the risk of heart attacks and strokes by 23% among 10,584 patients. Its potential to save lives worldwide is immense.

1 of 1

Story summary

Sotagliflozin, now FDA-approved for type 2 diabetes and kidney disease, is a game-changer in heart health. A groundbreaking trial led by Mount Sinai revealed that this innovative treatment slashed the risk of heart attacks and strokes by 23% among 10,584 patients. Its potential to save lives worldwide is immense.